Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance

Executive Summary

FDA is facing strong pressure from its own advisory committee members to finalize development standards for weight-loss drugs.
Advertisement

Related Content

Weighty Issues: GW Obesity Outcomes Project Tests Model For Patient Input In Drug Development
FDA Says Qnexa Needs CV Outcome Trial, Asks Cmte. To Consider Pre- Or Post-Approval Timeframe
Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Committee On CV Risk
Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval
Positive Two-Year Data Boost Prospects For Vivus' Qnexa
Meridia's CV Risks Not Distinguishable By Subgroups, FDA Cmte. Says
Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia
FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs

Topics

Advertisement
UsernamePublicRestriction

Register

PS052627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel